M acrophage migration inhibitory factor (MIF)
4 is a pleiotropic cytokine with a crucial role in the regulation of innate and adaptive immunity (1) . MIF is implicated in multiple autoimmune and inflammatory states, including sepsis, rheumatoid arthritis (RA), tumorigenesis, acute respiratory distress syndrome, glomerulonephritis, and enterocolitis (2) . MIF immunoneutralization or MIF deficiency is associated with protection against endotoxic shock and lethality, and marked anti-inflammatory effects in several experimental models of autoimmune disease.
The underlying molecular mechanisms of these observed biological effects are less well-understood. MIF-induced cellular activation is mediated via MAPK and the AP-1 transcription factor. MIF is thought to signal through classical receptor-dependent activation of MAPK through binding to CD74, the cell surface form of the MHC class-II-associated invariant chain (3) . In NIH3T3 cells, MIF induces sustained ERK MAPK activation associated with increased cellular proliferation and phospholipase A2 (PLA 2 ) activity (4) . In these same cells, MIF was shown to modulate adhesion-dependent sustained ERK MAPK activation and regulate cyclin D1 expression and cell cycle progression (5, 6) . MIF activates MAPK and AP-1 pathways in neuroblastoma cell lines (7) , osteoblasts, dermal fibroblasts (8) , and RA fibroblast like-synoviocytes (FLS) (9 -11) . In contrast, at supraphysiological concentrations, MIF also signals through nonreceptor-based pathways, via intracellular binding and activation of JAB1 leading to selective down-regulation of AP-1 activation (12) .
MIF, unlike other cytokines such as TNF, has a widespread tissue and cellular distribution including large preformed stores in immune cells and fibroblasts. This places MIF in an ideal position for regulation of immune and inflammatory events entrained by other factors such as endotoxin and cytokines. For example, endogenous MIF regulates TLR-4 expression to permit macrophage responses to endotoxin (13) . Whereas the role of endogenous MIF in responses to endotoxin is well-documented, the role of endogenous MIF in regulating responses to proinflammatory cytokines implicated in autoimmune diseases is poorly understood. The hypothesis that endogenous MIF does play a role in regulating cellular responses to other cytokines is supported by several observations. For example, immunoneutralization of MIF with anti-MIF mAb inhibits IL-1-and TNF-induced proliferation and IL-1-induced PLA 2 and cyclooxygenase-2 (COX-2) expression in RA FLS (9, 14) . MIF is known to exert autocrine and paracrine effects on immune cell activation, inducing IL-1 and TNF, leading in turn to further MIF production (15, 16) . We report here that endogenous MIF is required for IL-1-and TNF-induced MAPK activation and regulates the expression of receptors for these cytokines. These data provide a novel mechanism of action of MIF in the amplification of the immune response.
Materials and Methods

Cells
MIF
Ϫ/Ϫ mice were provided by Dr. J. R. David (Harvard School of Public Health, Boston, MA) (17, 18) , crossed for two generations with MIF wildtype (WT) C57BL/6 mice and experiments were performed with littermate MIF Ϫ/Ϫ and WT controls. Murine dermal fibroblasts (MDF) were isolated as described (18) . Mouse embryonal fibroblasts (MEF) were generated from WT and MIF Ϫ/Ϫ embryos at day 14.5. Cells were propagated in RPMI 1640/10% FCS (ICN Biomedicals) and passages 4 -6 used.
Plasmid constructs
The MIF coding region was amplified by PCR by using the following primers: 5-CACCATGCCGATGTTCATCGTAAAC-3 and 5-GGCGAA GGTGGAGTTGTTCC-3 (19) . The MIF open reading frame was verified by sequencing and cloned into a eukaryotic expression vector pcDNA 3.1 ϩ (Invitrogen Life Technologies). The following plasmid vectors were used: NFB-Luc, AP-1-Luc, pFC-MEKK, pPUC, pFA2-Elk1, pFA2-c-jun, or pFA2-ChOP (Promega).
Flow cytometry
The type 1 IL-1R (IL-1R) was detected following incubation with mAb against IL-1R. The p55 TNFR (p55 TNFR1) was detected following incubation with mAb against TNFR1, followed by biotin-conjugated Ab and allophycocyanin streptavidin compared with isotype control Abs (BD Pharmingen 
Western blot
Cells treated with 0.1 ng/ml IL-1␤ (Sigma-Aldrich), 1 ng/ml TNF-␣ (BioSource International) or 0.3 M sorbitol (Sigma-Aldrich) were examined for MAPK activation using Abs against IB␣, phospho-p38, phospho-ERK, phospho-JNK, phospho-MKK3/6 (MAPK kinase 3 and 6) or total p38, ERK, JNK MAPK (Santa Cruz Biotechnology; Cell Signaling Laboratories) as described previously (20) . Densitometry ratios of phospho-MAPKs normalized to total MAPK content were calculated and expressed as arbitrary units (AU) using Image Gauge software (version 3.46). MIF was measured by Western blot using Abs against MIF (R&D Systems) or ␤-actin (Santa Cruz Biotechnology).
EMSA
Nuclear extracts were prepared from cells treated with 0.1 or 5 ng/ml IL-1 for 1 h. Complementary oligonucleotides representing the consensus NF-B (5Ј-AGTTGA GGG GAC TTT CCC AGG C-3Ј) and AP-1 (5Ј-CGC TTGATG ACT CAGCCG GAA-3Ј) binding sites were annealed and labeled with 32 P. The NF-B or AP-1 nucleotide motifs are underlined. Sequence-specific binding was determined by incubation with nonradiolabeled WT or mutated probe, and supershift was detected with Abs against p50, p65, or c-fos and c-jun (Santa Cruz Biotechnology). Bands were analyzed using a PhosphoImager (Molecular Dynamics) and Image Gauge software (version 3.46).
Luciferase reporter assays
For AP-1 Luc assays, cells were transfected for 24 h with 1 g of AP-1-Luc reporter plasmid (Promega), and 50 ng of pCMV5-␤-GAL (Promega) using Fugene 6 (Roche), stimulated with 0.1 or 5 ng/ml IL-1␤ for 8 h. To investigate the effects of MEKK transfection on the transcriptional activity of AP-1, MIF Ϫ/Ϫ cells were cotransfected in DMEM/0.5% FCS with 50 ng of a negative control plasmid pFC-dbd and pFA2-Elk1, pFA2-c-jun, or pFA2-ChOP. Cells were simultaneously transfected with 50 ng of pFR-luc (Promega) for 16 h. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) and normalized to ␤-galactosidase.
Cellular proliferation assay
DNA synthesis was measured by [ 3 H]thymidine incorporation, as described (21) . Cells were treated with IL-1␤ or TNF-␣ for 48 h, pulsed for 18 h with 1 Ci/ml [ 3 H]thymidine (Amersham Biosciences) and radioactivity was determined by liquid scintillation counting.
ELISA
Cells were treated with 0.1 or 5 ng/ml IL-1␤ for 24 h, in the presence or absence of the IB phosphorylation inhibitor BAY-11-70-82 (10 M; Calbiochem) (22) and IL-6 was measured by ELISA.
Real-time PCR
WT and MIF
Ϫ/Ϫ cells were treated with 0.1 or 5 ng/ml IL-1 for 3 h. RNA was extracted using TRIzol reagent (Invitrogen Life Technologies). One microgram of RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen Life Technologies) and PCR amplification was performed on a Rotor-Gene 3000 (Corbett Research) using LightCycler DNA Master SYBR Green I kit (Roche). Murine IL-6 (23), IL-1R1 (forward, 5Ј-TGCGGGACACTAAGGAGAAA-3Ј; reverse, 5Ј-CTCTTCCC AATCCAGTTCCA-3Ј), p55 TNFR (24) , and ␤-actin (23) primers were used. mRNA was normalized to ␤-actin expression, and results were presented as the fold induction of mRNA expression relative to control samples.
Statistical analysis
Results are expressed as the mean Ϯ SEM. Analysis was performed using the Student t test, and p values Ͻ0.05 were considered statistically significant. All data are the result of at least three separate experiments.
Results
Endogenous MIF is required for IL-1-induced MAPK, AP-1 activation, and cell proliferation
We examined IL-1-induced MAPK activation in WT and MIF Ϫ/Ϫ cells. A total of 0.1 ng/ml IL-1 induced robust MAPK activation in WT cells (Fig. 1A, left panel) . In contrast, MIF Ϫ/Ϫ cells were markedly hyporesponsive to IL-1 activation of all three MAPK (p38, ERK, and JNK) phosphorylation at all time points. In dose response experiments, IL-1 induced dose-dependent phosphorylation of p38 in WT cells but this was impaired in MIF
We next examined downstream effects on AP-1 activation, using EMSA and reporter gene assays. For EMSA, cells were treated with 0.1 or 5 ng/ml IL-1 for 1 h and nuclear protein was extracted. Specific binding was shown using a radiolabeled AP-1 probe, and nonspecific binding with a mutated (mut) probe ( Fig. 1D ; p Ͻ 0.05). Thus, endogenous MIF was required for both basal and cytokine-induced cell proliferation. To ensure that MIF was indeed expressed by these cells, MIF expression in cell lysates was measured by Western blotting (Fig. 1E ). MIF protein was readily detected in WT, but not MIF Ϫ/Ϫ , cells. Expression of MIF was also confirmed in WT MEF. Confirmation of the normal regulation of MIF expression in both cell types was confirmed by the observation of increased MIF expression in response to the glucocorticoid dexamethasone in WT but not MIF Ϫ/Ϫ cells (Fig. 1E ).
Endogenous MIF is not essential for IL-1-induced NF-B activation and IL-6 expression
We next investigated IL-1-induced NF-B activation by analysis of IB ␣ degradation by Western blotting and NF-B EMSA. IL-1-induced IB ␣ degradation was similar in WT and MIF Ϫ/Ϫ cells ( Fig. 2A ). For EMSA, specific binding was shown using a radiolabeled NF-B probe, and nonspecific binding with a mutated (mut) probe (Fig. 2B, left panel) . Supershift was demonstrated with anti-p50, anti-p65 Abs. There was no difference detected in IL-1-induced NF-B DNA binding between MIF Ϫ/Ϫ and WT cells (Fig. 2B , right panel). These data indicate that endogenous MIF does not influence NF-B signaling in response to IL-1. We next sought to determine whether endogenous MIF is required in cytokine-induced proinflammatory cytokine production such as IL-6. IL-1-induced IL-6 expression was no different in MIF Ϫ/Ϫ and WT fibroblasts at either the transcriptional (data not shown) or posttranscriptional level (Fig. 2C ). In addition, IL-1-induced COX-2 expression was also comparable in MIF Ϫ/Ϫ and WT fibroblasts (data not shown). IL-1-induced IL-6 production is mediated predominantly by NF-B, and MAPK activation has been reported to contribute (10, 25) . We examined the NF-B dependence of IL-1-induced IL-6 production in WT and MIF Ϫ/Ϫ fibroblasts using an inhibitor of IB phosphorylation, BAY-11-70-82 (22) . In the presence of BAY-11-70-82, IL-1-induced IL-6 production was significantly inhibited in both WT and MIF Ϫ/Ϫ cells (Fig. 2D) . In MIF Ϫ/Ϫ cells, NF-B inhibition was associated with a near total (96%) inhibition of IL-1-induced IL-6. These data confirmed that IL-1-induced IL-6 expression in MIF Ϫ/Ϫ cells was NF-B dependent, and that endogenous MIF is not required for IL-1-induced NF-B-dependent IL-6 expression.
Impairment of IL-1-induced signaling occurs upstream of MAPK activation
To determine whether hyporesponsiveness to IL-1-induced p38 phosphorylation occurred at the level of p38 MAPK or upstream in the MAPK activation cascade, we next examined IL-1-induced activation of MKK3/6, the kinase upstream of p38 (26, 27) (Fig.  3A) . Compared with WT cells, MIF Ϫ/Ϫ fibroblasts were hyporesponsive to IL-1-induced MKK3/6 phosphorylation. These data demonstrated that in the absence of endogenous MIF, impairment of IL-1-induced signaling events occurred upstream of MAPK activation. To examine whether this defect was specific to cytokine receptor-induced signaling, cells were treated with the osmotic stress agent sorbitol (0.5 M) for 30 min (Fig. 3B) . In contrast to the impairment of p38 phosphorylation in IL-1-treated MIF Ϫ/Ϫ cells, phosphorylation of p38 induced by sorbitol was similar in MIF Ϫ/Ϫ and WT fibroblasts. This suggested that hyporesponsiveness of MIF Ϫ/Ϫ cell MAPK activation was stimulus specific, and that a reduction in endogenous MIF may impede MAPK signaling at some point between binding of IL-1 to the IL-1R complex and upstream of MEKK3/6 activation. (Table I) . Correspondingly, expression of the IL-1R1 mRNA was 10-fold lower in MIF Ϫ/Ϫ cells compared with WT cells (Fig. 3D ; p Ͻ 0.05).
Decreased type 1 IL-1R expression in MIF
Decreased p55 TNFR expression in MIF Ϫ/Ϫ cells
To investigate whether these effects were restricted to the IL-1R, we examined receptor expression of TNF. Cell surface p55 TNFR expression, as measured by flow cytometric analysis of TNFRpositive cells, was 3-fold lower in MIF Ϫ/Ϫ cells compared with WT cells (Fig. 3E ; p Ͻ 0.05). The expression of p55 TNFR, as measured by MFI, was 2.7-fold lower in MIF Ϫ/Ϫ compared with WT cells (Table I ; p ϭ 0.0006). Expression of p55 TNFR mRNA was similarly 2.5-fold lower in MIF Ϫ/Ϫ cells compared with WT cells (Fig. 3F ; p Ͻ 0.05).
Endogenous MIF is required for TNF-induced MAPK phosphorylation and cell proliferation
To confirm the functional significance of the observed reduction in TNFR expression in the absence of MIF, we examined TNF-induced MAPK activation and proliferation. A total of 1 ng/ml TNF induced robust MAPK activation in WT fibroblasts (Fig. 4A) . In contrast, TNF-induced ERK and JNK phosphorylation was impaired in MIF Ϫ/Ϫ cells, but in contrast to the results observed for IL-1 stimulation, p38 phosphorylation was intact. This indicates differential requirements for endogenous MIF in IL-1-compared with TNF-induced p38 MAPK activation. The role of endogenous MIF in MAPK-dependent TNF-induced cell activation was examined by cell proliferation. Similar to the results observed with IL-1 treatment, TNF-induced proliferation was significantly impaired in MIF Ϫ/Ϫ , compared with WT cells (Fig. 4B ). Our data indicated that up-regulation of cytokine receptor expression and receptordependent signaling events by endogenous MIF were not specific to the IL-1R1, but included regulation of TNFR1 expression and function.
Reconstitution of MIF in MIF Ϫ/Ϫ cells restores p55 TNFR expression
To confirm the regulation of cytokine receptors by MIF, we next investigated whether reconstitution of MIF in MIF Ϫ/Ϫ cells could restore cytokine receptor expression. We examined the effects of MIF transfection on p55 TNFR expression in studies using MIF Ϫ/Ϫ MEF. Reduced expression of p55 TNFR was confirmed in MIF Ϫ/Ϫ MEF compared with WT MEF by real-time PCR (Fig.  4C) . MIF Ϫ/Ϫ MEF were cotransfected with an EGFP reporter plasmid (pEGFP) together with an empty vector (pcDNA3.1 ϩ ) or an MIF-expressing vector (pcDNA3.1 ϩ MIF) for 48 h, then p55 TNFR expression was determined using flow cytometry as described in Materials and Methods. MIF transfection significantly increased p55 TNFR expression in MIF Ϫ/Ϫ MEF (Fig. 4D) . These findings were also confirmed in MDFs (Fig. 4E) . Expression of p55 TNFR was increased in both transfected (EGFP ϩ ) and untransfected (EGFP Ϫ ) cells, indicating autocrine-paracrine effects of MIF.
p55 TNFR expression is regulated via MAPK/AP-1 activation
We next investigated the molecular mechanism by which MIF modulates p55 TNFR expression. We hypothesized that downregulation of cytokine receptor expression in the absence of MIF is dependent on reduced MAPK/AP-1 transcriptional activity. The 
Discussion
Unlike other cytokines, abundant preformed and renewable stores of MIF are present in multiple immune and nonimmune cell types (4, 16, (31) (32) (33) . Constitutively expressed MIF has immunoregulatory functions in sepsis, inflammatory diseases, and tumorigenesis (4, 12, 13, 34, 35) . Thus, MIF is well-placed to potentially mediate facilitatory effects on the actions of other cytokines. MIF, TNF, and IL-1 have established roles in the pathogenesis of multiple immunopathologies, however, the mechanism(s) underlying their interactions is unknown. MIF is released as early as or earlier than IL-1 or TNF from cellular stores. In vivo, MIF deficiency or neutralization leads to protection against lethal bacterial sepsis and septic shock induced by Gram-negative endotoxin (17, 36) or Gram-positive exotoxin (37) , and amelioration of other chronic inflammatory diseases in the context of reduced MIF is associated with reduced circulating or local TNF and IL-1 production (17, 38, 39) . In vitro, MIF-deficient cells exhibit impaired TNF production in response to LPS, an effect mediated via MIF regulation of TLR-4-dependent cellular responses. Herein, we demonstrate that MIF regulates cellular receptor-dependent MAPK/AP-1 activation responses to key proinflammatory cytokines independent of NF-B.
We observed an essential role for endogenous MIF in cytokineinduced MAPK activation and basal and cytokine-induced MAPKdependent proliferation. This is consistent with the action of exogenous MIF on MAPK/AP-1 activation (3, 4, 8, 9, 40, 41) , and MAPK-dependent control of cell growth and tumorigenesis (7, 42, 43) . In NIH3T3 cells, MIF was required for ERK-induced cell proliferation (3, 4, 6) . In these same cells, both exogenous and endogenous MIF modulated adhesion-dependent sustained ERK activation, cyclin D1 expression, and cell cycle progression (5) . Similarly, MIF induces ERK-dependent RA FLS proliferation (9, 14) , whereas MIF immunoneutralization prevents cytokine-induced RA FLS proliferation (9) . MIF immunoneutralization also prevents IL-1-induced ERK-dependent PLA 2 and p38-dependent COX-2 expression (9), further supporting a permissive role of MIF in cytokine-induced MAPK-dependent cellular activation. In contrast, in our study, MIF was not required for cytokineinduced NF-B activation or NF-B-dependent IL-6 expression. This finding is in keeping with several previous reports. In RA FLS, for example, MIF does not induce NF-B at concentrations that activate ERK (21) . Moreover, anti-MIF mAb inhibits IL-1-induced cell activation, without effects on NF-B, and NF-B inhibition does not inhibit the biological effects of MIF (21) . Upregulation of NF-B DNA binding by MIF has been reported in RA FLS, but only at supraphysiologic concentrations (1 g/ml) (44), whereas induction of AP-1 DNA binding occurred at a more physiological concentration. MIF has been reported not to directly affect IB kinase activity (45) TNF-induced NF-B was identical in control and MIF antisense-transfected cells (46) . In contrast, in the context of reduced TLR-4 expression, MIF-deficient macrophages were hyporesponsive to LPS-induced NF-B activity (13) . Both p38 MAPK and NF-B have been reported to be implicated in the regulation of IL-6 expression (10, 25) . However, NF-B is essential as NF-B p50/p65-deficient fibroblasts do not express IL-6 in response to IL-1 (47) . In our study, IL-1-induced IL-6 remained intact despite a profound reduction in IL-1-induced p38 phosphorylation in MIF Ϫ/Ϫ cells, and NF-B antagonism lead to near complete abrogation of IL-1-induced IL-6. This suggests that NF-B is essential for IL-1-dependent IL-6 expression, and that this is independent of MIF. This is supported by data demonstrating no difference in LPS-induced IL-6 expression in MIF Ϫ/Ϫ or WT peritoneal macrophages (17) , and increased IL-6 expression in MIF Ϫ/Ϫ macrophages following cutaneous Leishmania major infection (48). MIF deficiency was associated with a marked reduction in TNF and IL-1R expression. An upstream defect in cytokine receptorinduced MAPK pathway activation was supported by impairment of cytokine-induced MKK3/6 phosphorylation in MIF Ϫ/Ϫ cells, whereas osmotic stress-induced p38 phosphorylation was intact. Reduced MAPK/AP-1 activation in MIF-deficient cells could be explained by, or alternately be the explanation for, reduced cytokine receptor expression. MIF up-regulates macrophage TLR-4 expression via the transcription factor PU.1 (13) . The IL-1R shares homology with TLR-4, and the promoter region contains binding sites for the PU.1 and AP-1 transcription factors (49, 50) . PU.1 is, however, only expressed in cells of myeloid differentiation lineage, and hence was not a candidate for regulation of IL-1R expression in fibroblasts (51) . Although little is known about the transcriptional regulation of p55 TNFR, the p75 TNFR is known to contain binding sites for AP-1 (52) . Transfection of MIF Ϫ/Ϫ cells with the upstream activator of MAPK, MEKK, was associated with activation of Elk 1, CHOP, and c-jun, and up-regulation of p55 TNFR expression. This suggests that MIF deficiency may impair proinflammatory cytokine receptor expression via the effects observed here on the MAPK/AP-1 pathway.
In addition to the role of endogenous MIF in regulating IL-1R1 and TNFR1 expression, we observed uncoupling of cytokine-induced MAPK-dependent cell proliferation from NF-B-dependent IL-6 expression. Binding of TNF to the p55 TNFR leads to activation of a multiprotein signaling complex with release of silencer of death domains, recruitment of TNFR-associated death domain protein, and the adaptor proteins TNFR-associated factor 2 (TRAF2) and receptor-interacting protein, which ultimately activate MAPK and NF-B pathways involved in inflammation, proliferation, and apoptosis (53) . Uncoupled receptor-dependent MAPK and NF-B signaling has been previously described for other TNFR superfamily members and TLR-4, either at the receptor level or through recruitment of other downstream components (54, 55) . Recent studies suggest that regulation of p55 TNFR and downstream components such as TRAF2 may also lead to divergent effects on MAPK and NF-B signaling. For example, downregulation of p55 TNFR by phosphorylation has been shown to selectively decrease MAPK activation in the presence of preserved NF-B function (56) . In contrast, preferential activation of MAPK but not NF-B has been reported to be determined by the location of the p55 TNFR in lipid or nonlipid raft components of the plasma membrane (57) . Upon activation by TNF, p55 TNFR is segregated to predominantly lipid rafts in the plasma membrane. In parallel, ERK MAPK localizes to the same compartment whereas IB remains in the nonlipid compartment. In addition, downstream components of the p55 TNFR complex such as TRAF2 recruited by silencer of death domains display similar diversity in regulation of MAPK independent of NF-B (58, 59).
In conclusion, endogenous MIF has been shown here to exert a permissive regulatory role in cellular responsiveness to key proinflammatory cytokines TNF and IL-1 via up-regulation of cytokine receptor-dependent MAPK signaling independent of NF-B. Autocrine up-regulation of cytokine-mediated MAPK-dependent events by endogenous MIF may provide a previously unrecognized mechanism for the amplifying role of MIF in immunity, and tumorigenesis, and the observed benefits of MIF deficiency in experimental models of inflammatory disease. Due to the widespread expression of endogenous MIF, IL-1R1, and the p55 TNFR in both immune and nonimmune cells, anti-MIF therapies would be anticipated to have significant anti-inflammatory effects. These data emphasize the role of MIF in regulating the set-point of the cytokine activation response and the potential impact of anti-MIF strategies in inflammatory disease.
